Skip to contentpdufa.bio

PIXCLARA (floretyrosine F-18): FDA NDA 218592

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 218592 is the FDA application for PIXCLARA (floretyrosine F-18). The FDA's Orange Book lists the applicant of record as TELIX PHARMACEUTICALS US INC and the first approval on it as Sep 11, 2026. Code names used in development: TLX101-Px, TLX101-CDx. Owner today: Telix Pharmaceuticals Limited (ASX/Nasdaq: TLX).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 218592 · Orange Book NDA 218592

Names for this drug

Brand name (FDA)PIXCLARA
Orange Book trade name: PIXCLARA
Active ingredient (FDA)FLORETYROSINE F-18
Code nameTLX101-Px
Source: Telix Pharmaceuticals press release, Sep 14, 2026
“Pixclara (TLX101-Px) is also the subject of a Phase 3 registrational study for potential indication expansion”
Code nameTLX101-CDx
Source: Telix Pharmaceuticals press release, Oct 24, 2024
“TLX101-CDx (Pixclara) is a PET imaging agent, which has been granted fast track and orphan drug”

Who holds the application

FDA applicant of recordTELIX PHARMACEUTICALS US INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayTelix Pharmaceuticals Limited (TLX)
Source: Telix Pharmaceuticals press release, Sep 14, 2026
“(ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA)”

Products on NDA 218592 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001PIXCLARASOLUTION;INTRAVENOUS5-300mCi/MLSep 11, 2026

FDA decisions we track for this drug

Pixclara (floretyrosine F 18; TLX101-Px)TLX · Decided

Drug page: /drug/pixclara

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.